The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

Recruiting now · Phase 2

Conditions studied: Cryptosporidium Infection

In brief

This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Key facts

Study ID

NCT07388615

Run by

Al-Azhar University

People needed

60

Starts

2026-01-18

Expected to finish

2026-08-01

Last updated by the study team

2026-02-05

Who can join

Age: 5 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Cryptosporidiosis Disease
• Age from 5-12 years
• Immunocompromised children
• Not receiving any drugs causing immunosuppression

You may not qualify if…

• Patients undergoing organ transplantation
• Patients suffering from autoimmune diseases.
• Patients suffering from hypersensitivity of this plant extract

Where it is running

• National Nutritional Institute — Cairo, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.